Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come

Diagnostic and treatment algorithms in non-small cell lung cancer (NSCLC) are evolving at a never-before-seen pace. Histological subtyping to maximise treatment efficacy and avoid toxicity has marked the beginning of the revolution, opening the way to molecular characterisation to guide genomically...

Full description

Saved in:
Bibliographic Details
Published inEcancermedicalscience Vol. 11; p. 787
Main Authors Toschi, Luca, Rossi, Sabrina, Finocchiaro, Giovanna, Santoro, Armando
Format Journal Article
LanguageEnglish
Published England Cancer Intelligence 30.11.2017
Subjects
Cancer therapies
Chemotherapy
Clinical trials
FDA approval
Growth factors
Histology
Immunotherapy
Lung cancer
Oncology
Patients
Review
Studies
Tumors
program death 1 receptor (PD-1)
epidermal growth factor receptor (EGFR)
checkpoint inhibitors
non-small cell lung cancer (NSCLC)
anaplastic lymphoma kinase (ALK)
Online AccessGet full text

Cover

More Information
Summary:Diagnostic and treatment algorithms in non-small cell lung cancer (NSCLC) are evolving at a never-before-seen pace. Histological subtyping to maximise treatment efficacy and avoid toxicity has marked the beginning of the revolution, opening the way to molecular characterisation to guide genomically driven treatments with targeted agents, led by Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) inhibitors. More recently, agents against the Program Death 1 receptor (PD-1) and ligand 1 (PD-L1) have entered the clinical arena, offering new hope to NSCLC patients, although several uncertainties remain to be elucidated. Here, we review the most clinically relevant advances in the diagnosis and treatment of NSCLC in the past decade.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1754-6605
1754-6605
DOI:10.3332/ecancer.2017.787